MedTrace Logo

Continuous Infusion Versus Intermittent Boluses of Cisatracurium in the Early Management of Pediatric ARDS

NCT05153525 · Status: UNKNOWN · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2022-06-22

No results posted yet for this study

Summary

The aim of this work is to compare continuous infusion vs on need intermittent boluses of Cisatracurium in the early management of pediatric acute respiratory distress syndrome

Conditions

  • Respiratory Distress Syndrome, Pediatric
  • Acute Lung Injury/Acute Respiratory Distress Syndrome (ARDS)

Interventions

DRUG

Intermittent boluses of Cisatracurium

Thirty children with ARDS will be treated with intermittent boluses of Cisatracurium (0.1-0.15 mg/kg/dose).

DRUG

Intravenous infusion of Cisatracurium for 24 hours

Thirty children with ARDS will be treated with intravenous infusion of Cisatracurium titrated from 1 mic/kg/min till reaching the desired effect for 24 hours.

Sponsors & Collaborators

  • Tanta University

    lead OTHER

Principal Investigators

  • Mohamed Khaled Talaat, PharmD · Tanta University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
1 Month
Max Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-01-06
Primary Completion
2022-07-30
Completion
2022-08-05
FDA Drug
Yes

Countries

  • Egypt

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05153525 on ClinicalTrials.gov